Infusionsreaktioner, karakteriseret ved et tilbagevendende mønster af symptomer, der optræder under infusion med Naglazyme, blev observeret hos 30 (56%) af de 54 patienter, der blev behandlet med Naglazyme i samtlige kliniske studier.
Infusion reactions, characterized by a recurring pattern of symptoms occurring during Naglazyme infusion, were observed in 30 (56%) of the 54 patients treated with Naglazyme across all clinical studies.